[Federal Register Volume 65, Number 89 (Monday, May 8, 2000)]
[Notices]
[Page 26646]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-11401]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Issuer Delisting; Notice of Application To Withdraw From Listing 
and Registration; (Maxim Pharmaceuticals, Inc., Common Stock, $.001 Par 
Value, and Redeemable Common Stock Purchase Warrants Expiring July 10, 
2001) File No. 1-14430

May 2, 2000.
    Maxim Pharmaceuticals, Inc. (``Company'') has filed an application 
with the Securities and Exchange Commission (``Commission''), pursuant 
to Section 12(d) of the Securities Exchange Act of 1934 (``Act'') \1\ 
and Rule 12d2-2(d) thereunder,\2\ to withdraw the securities described 
above (``Securities'') from listing and registration on the American 
Stock Exchange LLC (``Amex'') and under Section 12(b) of the Act.\3\
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78l(d).
    \2\ 17 CFR 240.12d2-2(d).
    \3\ 15 U.S.C. 78l(b).
---------------------------------------------------------------------------

    The Company, whose business is biotechnology, has undertaken to 
transfer trading in its Securities from the Amex to the National Market 
of the Nasdaq Stock Market, Inc. (``Nasdaq''), which it considers to be 
the preeminent marketplace for the securities of biotechnology 
companies. The Company has registered its Securities pursuant to 
Section 12(g) of the Act \4\ by filing a Registration Statement on Form 
8-A with the Commission on April 26, 2000. The Securities subsequently 
became designated for quotation and began trading on the Nasdaq 
National Market, and were simultaneously suspended from trading on the 
Amex, on April 27, 2000. In making the determination to withdraw its 
Securities from listing and registration on the Amex in conjunction 
with the commencement of trading on the Nasdaq, the Company hopes to 
avoid both the costs of maintaining dual listings and potential 
fragmentation of the market for its Securities.
---------------------------------------------------------------------------

    \4\ 15 U.S.C. 78l(g).
---------------------------------------------------------------------------

    The Company has stated that it has complied with the Rules of the 
Amex governing the withdrawal of its Securities from listing and 
registration on the Exchange, and that the Amex in turn has indicated 
that it will not oppose such withdrawal.
    The Company's application relates solely to the withdrawal of the 
Securities from listing and registration on the Amex and shall have no 
effect upon the Securities' designation for quotation and trading on 
the Nasdaq National Market and registration under Section 12(g) of the 
Act.\5\
---------------------------------------------------------------------------

    \5\ Id.
---------------------------------------------------------------------------

    Any interested person may, on or before May 23, 2000, submit by 
letter to the Secretary of the Securities and Exchange Commission, 450 
Fifth Street, N.W., Washington, D.C. 20549-0609, facts bearing upon 
whether the application has been made in accordance with the rules of 
the Amex and what terms, if any, should be imposed by the Commission 
for the protection of investors. The Commission, based on the 
information submitted to it, will issue an order granting the 
application after the date mentioned above, unless the Commission 
determines to order a hearing on the matter.
    For the Commission, by the Division of Market Regulation, 
pursuant to delegated authority.\6\

    \6\ 17 CFR 200.30-3(a)(1).

Jonathan G. Katz,
Secretary.
[FR Doc. 00-11401 Filed 5-5-00; 8:45 am]
BILLING CODE 8010-01-M